Pepticom Ltd. founded in 2011, is focused on the discovery of novel peptide-drug candidates. Pepticom’s key asset is a unique Artificial Intelligence platform for peptide design, based on the target's solved crystal structure. Pepticom operates in various markets, generating innovative binding peptides for diverse targets. Past successful discoveries include active molecules in metabolic diseases, Alzheimer's disease and Immunomodulators.
Dr. Immanuel Lerner CEO
Dr. Amit Michaeli Co-Founder and CTO
Dr. Maayan Elias Robicsek Business Development Officer
Dr. Shaul Lerner Chief Biologist
Dr. Lev Shapira PeptiCov project leader
Ms. Guila Assayag Scientist
Ms. Dikla Haham Research assistant